Alpelisib is an oral α-specific PI3K kinase inhibitor that has shown efficacy in targeting PIK3CA-mutated cancer (André et al., 2019), and its combination with fulvestrant has recently been approved by the US Food and Drug Administration for the treatment of metastatic or otherwise advanced breast cancer. Here, PIK3CA is linked to breast cancer.